Related Experiment Video
Updated: Aug 3, 2025
04:22
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
924
Sex Differences in Alzheimer's Disease.
Neelum T Aggarwal1, Michelle M Mielke2
1Department of Neurological Sciences, Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 West Harrison Street, Suite 1000, Chicago, IL 60612, USA.
Neurologic Clinics
|April 8, 2023
Summary
Investigating sex and gender differences in Alzheimer's dementia (AD) requires accounting for longevity and comorbidities. Understanding these factors is crucial for developing targeted AD prevention strategies.
Area of Science:
- Neurology
- Epidemiology
- Gerontology
Background:
- Alzheimer's dementia (AD) exhibits observed sex and gender differences.
- Factors like longevity, survival bias, and comorbidities may influence these observed differences.
- Biological and psychosocial elements can differentially impact AD risk and progression.
Purpose of the Study:
- To emphasize the need for epidemiological evaluation of sex and gender differences in AD.
- To highlight the importance of considering various factors influencing AD risk and progression.
- To underscore the necessity of identifying sex differences in AD biomarkers for prevention trials.
Main Methods:
- Review of epidemiological data on Alzheimer's dementia.
- Analysis of medical, genetic, psychosocial, behavioral, and hormonal factors.
- Evaluation of sex differences in AD progression, cognitive function, and biomarkers.
Main Results:
- Observed sex differences in AD may be influenced by longevity, survival bias, and comorbidities.
- Medical, genetic, psychosocial, behavioral, and hormonal factors differentially affect AD risk and progression.
- Further evaluation of sex differences in AD progression and biomarkers is required.
Conclusions:
- Epidemiological assessment is vital for understanding sex and gender differences in AD.
- Identifying sex-specific AD biomarkers is critical for effective prevention strategies.
- Longitudinal studies are needed to track changes in AD biomarkers across the lifespan.
More Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
555
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
555
01:22Alzheimer's Disease: Treatment
232
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232
01:30Dementia
150
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
150